Pd-166285 Hydrate

Not available outside of the UK & Ireland.

Application

PD-166285 Hydrate has been used as a fibroblast growth factor (FGF) signaling inhibitor to study its effects on LIM-homeodomain gene 9 (Lhx9) expression during limb development in mice.

Biochem/physiol Actions

PD-166285 hydrate is a broad spectrum protein tyrosine kinase inhibitor; Src and FGFR kinase inhibitor.

PD-166285 is also a potent inhibitor of Wee-1, epidermal growth factor receptor, and platelet-derived growth factor receptorβ subunit (PDGFR-β). It also exhibits its inhibitory effects against mitogen-activated protein kinase (MAPK) and protein kinase C (PKC). PD-166285 shows antiproliferative and anti-migratory effects due to which it may be used as a therapeutic agent against atherosclerosis, restenosis, and cancer.

Features and Benefits

This compound is featured on the FGFR page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Kinase Phosphatase Biology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle